- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03936816
The Implementation of Real-time PCR - Intrapartum GBS (Group B Streptococcus) Colonization to Reduce Antibiotic Prophylaxis
The Implementation of Real-time PCR for Detection of Intrapartum GBS (Group B Streptococcus) Colonization as a Way to Reduce Antibiotic Prophylaxis Usage
Study Overview
Detailed Description
The investigators intend to perform a cohort prospective trial in the delivery ward of CARMEL medical center. Pregnant women that are admitted to our ward and need to receive GBS (group B Streptococcus) prophylaxis either due to a positive GBS culture screen done at 35-37 weeks or by having risk factors for prophylactic antibiotic treatment (prolonged rupture of membranes, preterm delivery, GBS bacteriuria during current pregnancy) will be tested by a double vaginal swab (PCR and culture). Pregnant women that were screened positive at 35-37 weeks, those who had GBS bacteriuria during pregnancy and those who labor prematurely will be tested upon admission. Patients that have prolonged rupture of membranes (18 hours) will be tested by a double vaginal swab after 17 hours and prior to antibiotics administration.
All patient will be treated with GBS prophylactic antibiotics according to the culture screen done at 35-37 weeks or by risk factors (current protocol guidelines). Culture and PCR will be sent to the lab and the results will be revealed after delivery (the staff and patients will be blinded to the results of the culture and PCR until after delivery) in order to assess the number of patients that were treated with antibiotics unnecessarily.
The investigators intend to recruit 300 patients of which half will need antibiotics because of a positive culture at 35-37 weeks and half because of having risk factors. We decided to omit patients that will have fever during labor (a risk factor that necessitates GBS prophylaxis) because these patients will receive broad spectrum antibiotics anyway.
The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel
- Carmel Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
inclusion criteria:
- Pregnant patients that were screened positive by a culture at 35-37 weeks (those patients will be screened with a vaginal double swab upon admission to labor ward).
- Pregnant patients with GBS bacteriuria in current pregnancy (those patients will be screened with a vaginal double swab upon admission to labor ward).
- Pregnant patients in preterm labor before 37 weeks (those patients will be screened with a vaginal double swab upon admission to labor ward).
- Pregnant patients with prolonged rupture of membranes (those patients will be screened with a vaginal double swab after 17 hours and prior to antibiotics treatment).
- All patients have signed an informed consent.
Exclusion Criteria:
- Pregnant patients that do not want to participate in the study.
- Pregnant patients that fever is the risk factor for GBS prophylaxis.
- Pregnant patients that were screened negative by a culture at 35-37 weeks.
- Pregnant patient with PPROM (before 34 weeks).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GBS screened positive
150 patients that were screened positive by culture at 35-37 weeks gestational age.
|
The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
|
GBS unknown with risk factors
150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
|
The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intrapartum GBS PCR in patients that require GBS prophylaxis
Time Frame: The patients will be assessed once upon admission to labor room by having a double vaginal swab for GBS PCR and GBS culture
|
The investigators intend to compare the number of patients that require GBS prophylaxis because they were screened positive (at 35-37 weeks) or have risk factors during labor (300 patients) to the number of patients that will be found positive on real time PCR upon admission to labor room.
In that way the reduction (in percentage) for the need of GBS prophylaxis will be assessed.
|
The patients will be assessed once upon admission to labor room by having a double vaginal swab for GBS PCR and GBS culture
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
validity of GBS PCR
Time Frame: The patients will be assessed once upon admission to labor room by having a double vaginal swab for GBS PCR and GBS culture
|
Each patient that will be recruited will be sampled vaginally by a double swab for PCR and culture for GBS.
The investigators intend to compare the number positive results of PCR GBS to the number of positive culture results (which is considered gold standard) and in that way to determine the sensitivity and specificity of PCR for GBS.
|
The patients will be assessed once upon admission to labor room by having a double vaginal swab for GBS PCR and GBS culture
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CMC-19-0027-CTIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GBS
-
The Baruch Padeh Medical Center, PoriyaClalit Health ServicesUnknown
-
Luminex CorporationCompleted
-
Hadassah Medical OrganizationUnknown
-
Peking Union Medical College HospitalCompleted
-
GlaxoSmithKlineNovartis VaccinesCompletedStreptococcus Agalactiae | GBS DiseaseUnited States
-
Aga Khan UniversityEmory University; Centers for Disease Control and PreventionCompletedGroup B Streptococcus (GBS) ColonizationPakistan
-
Novartis VaccinesCompletedGroup B Streptococcus (GBS) DiseaseSwitzerland
-
NovartisNovartis VaccinesCompletedA Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS VaccineGroup B Streptococcus (GBS) DiseaseSwitzerland
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompletedInvasive Group B Streptococcus (GBS) DiseaseSwitzerland
Clinical Trials on GBS vaginal double swab
-
The Nazareth Hospital, IsraelCompletedStreptococcus B Carrier State Complicating PregnancyIsrael
-
Cairo UniversityCompletedFirst Trimester AbortionEgypt
-
Anne's Day LtdCareggi Hospital; Lindus HealthActive, not recruitingChlamydia | Gonorrhea | Human Papilloma Virus | Bacterial VaginosisUnited Kingdom
-
University of LuebeckRecruitingSexually Transmitted InfectionGermany
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
The University of Texas Health Science Center at...CompletedCandidiasis | Vaginitis | Vaginosis, Bacterial | Vaginal Discharge | TrichomonasUnited States
-
University Hospital, Clermont-FerrandNot yet recruitingPremature Birth | Vaginal FloraFrance
-
Assiut UniversityUnknown
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCesarean Section | Microbiome | Vaginal Seeding | NoseUnited States
-
University Hospital, GhentCenter for Microbial Ecology and Technology - Ghent UniversityCompletedRepeated Implantation Failure | Normal FertileBelgium